# 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients

NCT07077213

| | |
|---|---|
| **Status** | RECRUITING |
| **Sponsor** | Children's Hospital Medical Center, Cincinnati |
| **Enrollment** | 30 participants |

## Key Eligibility Criteria

### Inclusion (9)

- Greater than or equal to 18 years of age
- Culture confirmation of M. tuberculosis, or sputum positive by molecular testing (GeneXpert).
- Imaging evidence of suspected M. tuberculosis disease involving lung, and possible additional other sites of involvement. Modalities can include any imaging modality such as chest x-ray, CT, ultrasound, MRI, 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (\[18F\]FDG) PET/CT, bone scan.
- TB treatment initiation within 6-weeks by the time of the study PET/CT scan OR within 6-weeks after receiving 6-months of TB treatments. Using this approach, we will be able to assess fibrosis in TB patients at treatment initiation as well as having received TB treatments. The same patient may be re-consented for a scan at the later time-point.
- Subject is willing to give written informed consent.

... and 4 more (see full listing online)

### Exclusion (5)

- Inadequate venous access (two antecubital or equivalent venous access sites are required for study drug injection and pharmacokinetics (PK) blood sampling, respectively)
- Lactating females
- Administered a radioisotope within 5 physical half-lives as part of a research study prior to study enrollment.
- Determined to have prior (external) radiation exposure from research studies which will exceed Radioactive Drug Research Committee (RDRC) annual radiation exposure limit of 5 rems.
- Any medical condition that in the judgment of the investigator would make the patient inappropriate for entry into this study.

## Locations (1 total)

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States